Bian Chun'an, Li Zhongyou, Xu Youtao, Wang Jie, Xu Lin, Shen Hongbing
Department of Thoracic Surgery, Jiangsu Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital of Jiangsu Province, Nanjing 210009, China;Nanjing Jiangbei People's Hospital, Nanjing 210048, China.
Department of Thoracic Surgery, Jiangsu Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital of Jiangsu Province, Nanjing 210009, China.
Zhongguo Fei Ai Za Zhi. 2015 Jan;18(1):23-8. doi: 10.3779/j.issn.1009-3419.2015.01.04.
P53 is a tumor protein that acts as a tumor suppressor. The mutation of P53 may cause loss of tumor suppressor functions and gain of functions favoring cellular proliferation and apoptosis inhibition. The clinical implications of the tumor protein P53 gene (TP53) mutation in lung adenocarcinoma are indefinite. The aim of this study is to explore the clinical significance of the mutant P53 protein expression in lung adenocarcinoma tissues.
The clinicopathological data of 120 lung adenocarcinoma patients who underwent surgery were retrospectively analyzed. The mutant P53 protein expression was detected using the immunohistochemical method. Furthermore, the relationship between the mutant P53 expression and the clinicopathological parameters was analyzed using the Chi-square test, whereas that between the mutant P53 expression and overall survival was estimated using the Kaplan-Meier method and Cox regression model.
The mutant P53 protein expression rate was 63.3%. Accordingly, the mutant P53 expression was significantly associated with tumor size (P=0.041) and clinicopathological stage (P=0.025). On the one hand, a univariate survival analysis showed that tumor size (P=0.031), lymph node metastasis (P<0.001), clinicopathological stage (P<0.001), and mutant P53 expression (P=0.038) were associated with overall survival. On the other hand, a multivariate survival analysis showed that lymph node metastasis (P=0.014) was an independent poor prognostic factor for overall survival.
Patients with lung adenocarcinoma with mutant TP53 had a poor outcome. Accordingly, the mutant P53 protein may serve as a molecular prognosis marker for lung adenocarcinoma patients.
P53是一种作为肿瘤抑制因子的肿瘤蛋白。P53突变可能导致肿瘤抑制功能丧失，并获得有利于细胞增殖和抑制细胞凋亡的功能。肿瘤蛋白P53基因（TP53）突变在肺腺癌中的临床意义尚不明确。本研究旨在探讨突变型P53蛋白表达在肺腺癌组织中的临床意义。
回顾性分析120例行手术治疗的肺腺癌患者的临床病理资料。采用免疫组化方法检测突变型P53蛋白表达。此外，采用卡方检验分析突变型P53表达与临床病理参数之间的关系，而采用Kaplan-Meier法和Cox回归模型评估突变型P53表达与总生存之间的关系。
突变型P53蛋白表达率为63.3%。因此，突变型P53表达与肿瘤大小（P=0.041）和临床病理分期（P=0.025）显著相关。一方面，单因素生存分析显示肿瘤大小（P=0.031）、淋巴结转移（P<0.001）、临床病理分期（P<0.001）和突变型P53表达（P=0.038）与总生存相关。另一方面，多因素生存分析显示淋巴结转移（P=0.014）是总生存的独立不良预后因素。
TP53突变的肺腺癌患者预后较差。因此，突变型P53蛋白可作为肺腺癌患者的分子预后标志物。
